Health

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Saturday, November 16, 2019 - 3:45pm

In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile.

Key Points: 
  • In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile.
  • Full study results were presented during a late-breaking science session at the American Heart Association (AHA) Scientific Sessions in Philadelphia.
  • The data from ORION-10 show that inclisiran lowers LDL-C significantly and sustains reductions over a six-month period with a safety profile similar to placebo.
  • A similar proportion of patients in the placebo and inclisiran groups experienced at least one serious treatment emergent adverse event (26.3% vs. 22.4%).

Global Sinus Dilation Devices Market 2019-2023| Evolving Opportunities with Intersect ENT, Inc. and Medtronic | Technavio

Saturday, November 16, 2019 - 2:00am

Technavio has been monitoring the global sinus dilation devices market and the market is poised to grow by USD 1.2 billion during 2019-2023 at a CAGR of 9% during the forecast period.

Key Points: 
  • Technavio has been monitoring the global sinus dilation devices market and the market is poised to grow by USD 1.2 billion during 2019-2023 at a CAGR of 9% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20191115005422/en/
    Technavio has announced its latest market research report titled global sinus dilation devices market 2019-2023 (Graphic: Business Wire)
    Read the 131-page research report with TOC on "Sinus Dilation Devices Market Analysis Report by Product (Balloon sinus dilation devices, Endoscopes, Sinus stents, and Surgical instruments), by Procedure (standalone sinus dilation and hybrid sinus dilation), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023".
  • In addition, technological advances in sinusitis treatment are anticipated to further boost the growth of the sinus dilation devices market.
  • Major Five Sinus Dilation Devices Market Companies:
    Intersect ENT, Inc. is headquartered in the US and operates under the business segment: Unified business segment.

Advisory - Duchesnay Inc. recalls certain lots of PregVit and PregVit folic 5 prenatal and postpartum vitamin-mineral supplements because of a packaging error

Saturday, November 16, 2019 - 1:49am

The company estimates the issue affects a very small number of products in certain lots (see the table below) and not all products.

Key Points: 
  • The company estimates the issue affects a very small number of products in certain lots (see the table below) and not all products.
  • Women taking all pink tablets will not receive the intended vitamin and mineral supplements.
  • Properly packaged products should contain two blister packs, with each blister pack containing 15 pink tablets and 15 blue tablets.
  • The company received a complaint of a product containing a blister pack that contained all pink tablets and no blue tablets.

Fuse Medical Reports Third Quarter 2019 Results

Friday, November 15, 2019 - 11:44pm

Fuse Medical, Inc., (OTCPK: FZMD), emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it has filed its quarterly report on Form 10-Q for the third quarter ended September 30, 2019, with the United States Securities and Exchange Commission, on Thursday, November 14, 2019.

Key Points: 
  • Fuse Medical, Inc., (OTCPK: FZMD), emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it has filed its quarterly report on Form 10-Q for the third quarter ended September 30, 2019, with the United States Securities and Exchange Commission, on Thursday, November 14, 2019.
  • Christopher C. Reeg, Chief Executive Officer, commented, With the filing of our third quarter of 2019 results we believe our continued investment in product development has been instrumental to our integrated distribution and manufacturing business model.
  • Our objective in 2019 was to expand product development in our spine and orthopedic implant offerings, for which we expect to see continued growth and acceptance for the rest of 2019 with significant ramp-up throughout 2020.
  • Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace.

Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

Friday, November 15, 2019 - 11:39pm

Bristol-Myers Squibb Company (NYSE:BMY) (Bristol-Myers Squibb) announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the Exchange Offers) notes (the Celgene Notes) issued by Celgene Corporation (NASDAQ:CELG) (Celgene) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the Bristol-Myers Squibb Notes) and cash and the related consent solicitations (the Consent Solicitations) being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments (the Amendments) to the indentures governing the Celgene Notes.

Key Points: 
  • Bristol-Myers Squibb Company (NYSE:BMY) (Bristol-Myers Squibb) announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the Exchange Offers) notes (the Celgene Notes) issued by Celgene Corporation (NASDAQ:CELG) (Celgene) for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company (the Bristol-Myers Squibb Notes) and cash and the related consent solicitations (the Consent Solicitations) being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments (the Amendments) to the indentures governing the Celgene Notes.
  • As previously announced, the Exchange Offers and Consent Solicitations are currently scheduled to expire at 5:00 p.m., New York City time, on November 20, 2019 (the Expiration Date).
  • As a result, Bristol-Myers Squibb currently expects that there will be no further extension of the Expiration Date as it is anticipated that the Merger will be completed on the Expiration Date.
  • The settlement date for the Exchange Offers is expected to occur on November 22, 2019.

Global Medical Sensors Market 2019-2023 | Evolving Opportunities With First Sensor AG and HONEYWELL INTERNATIONAL INC. | Technavio

Saturday, November 16, 2019 - 12:00am

View the full release here: https://www.businesswire.com/news/home/20191115005384/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191115005384/en/
    Technavio has announced its latest market research report titled global medical sensors market 2019-2023.
  • The market is driven by the rising demand for medical sensors in home care settings.
  • In addition, the growing demand for digital medicine and sensor-enabled pills is anticipated to further boost the growth of the medical sensors market.
  • Major Five Medical Sensors Market Companies:
    First Sensor AG is headquartered in Germany and operates the business under various segments such as Industrial, Medical, and Mobility.

Intermountain Healthcare Leaders Deliver Annual Report to the Community

Friday, November 15, 2019 - 10:10pm

Intermountain Healthcares leaders say the organization is making strides to improve care and make it more affordable for patients and communities.

Key Points: 
  • Intermountain Healthcares leaders say the organization is making strides to improve care and make it more affordable for patients and communities.
  • In an annual community report on Friday to 400 community and healthcare officials in Salt Lake City, Intermountain leaders outlined how the organization is changing its model of healthcare delivery to stay strong and stable for future generations, and also engaging in many innovations.
  • Bert Zimmerli, Intermountains executive vice president and chief financial officer, pointed out that healthcare nationally and in Utah is too expensive.
  • He outlined how Intermountain is changing its model of healthcare delivery to help make it more affordable.

Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

Friday, November 15, 2019 - 9:55pm

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASDAQ:CELG), thereby permitting the parties to close the transaction.

Key Points: 
  • Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASDAQ:CELG), thereby permitting the parties to close the transaction.
  • Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for Bristol-Myers Squibbs pending merger with Celgene.
  • Bristol-Myers Squibb has now satisfied all regulatory requirements under the merger agreement to complete the acquisition of Celgene and expects to close the transaction on November 20, 2019.
  • In connection with the proposed transaction between Bristol-Myers Squibb Company (Bristol-Myers Squibb) and Celgene Corporation (Celgene), on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the SEC) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb.

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

Friday, November 15, 2019 - 9:19pm

The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.

Key Points: 
  • The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.
  • These discussions aim to explore potential strategic alternatives that could provide greater value creation opportunities than the already strong stand-alone growth prospects for the Company, taking into consideration the interests of QIAGEN's stakeholders including its shareholders.
  • There is no guarantee or certainty that these discussions will lead to a recommended firm offer to all shareholders of the Company.
  • Such statements include statements with respect to the Company's strategic plans and exploration of strategic alternatives.

MedMen Announces Layoffs and Overall Plan to Achieve Positive EBITDA

Friday, November 15, 2019 - 9:00pm

MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) (MedMen or the Company), a leading cannabis retailer with operations across the U.S., today announced a strategic plan (the Plan) to achieve its target of positive EBITDA by the end of calendar year 2020.

Key Points: 
  • MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) (MedMen or the Company), a leading cannabis retailer with operations across the U.S., today announced a strategic plan (the Plan) to achieve its target of positive EBITDA by the end of calendar year 2020.
  • MedMen believes the Company can execute this plan while still growing its retail presence and maintaining a best-in-class retail experience.
  • We must unlock our operating leverage and bring the Company to positive EBITDA.
  • We thank everyone for their hard work and dedication to MedMen, and we will now set our sights on achieving positive EBITDA by the end of calendar year 2020.